You are viewing the site in preview mode

Skip to main content

Table 3 Treatment-related adverse events

From: Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study

Adverse Events

All

Grade 1–2

Grade 3–4

Leukopenia

15 (93.8)

12 (75.0)

3 (18.8)

Neutropenia

13 (81.3)

8 (50.0)

5 (31.3)

Anaemia

8 (50.0)

8 (50.0)

-

Thrombocytopenia

4 (25.0)

3 (18.8)

1 (6.2)

Fatigue

5 (31.3)

5 (31.3)

-

Nausea/vomiting

6 (37.5)

5 (31.3)

1 (6.2)

Decreased appetite

5 (31.3)

5 (31.3)

-

Headache

1 (6.2)

1 (6.2)

-

Pneumonia

1 (6.2)

-

1 (6.2)

Oedema peripheral

1 (6.2)

1 (6.2)

-

Fever

4 (25.0)

4 (25.0)

-

Numbness

2 (12.5)

2 (12.5)

-

Cardiac failure

1 (6.2)

1 (6.2)

-